NASDAQ:PLXP - PLx Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.00 -0.05 (-1.23 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$4.00
Today's Range$4.00 - $4.00
52-Week Range$3.20 - $9.41
Volume692 shs
Average Volume4,153 shs
Market Capitalization$34.91 million
P/E Ratio-2.05
Dividend YieldN/A
Beta1.91
PLx Pharma logoPLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The company's product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.

Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PLXP
CUSIPN/A
Phone713-842-1249

Debt

Debt-to-Equity Ratio0.71
Current Ratio17.68
Quick Ratio17.69

Price-To-Earnings

Trailing P/E Ratio-2.05
Forward P/E Ratio-2.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$780,000.00
Price / Sales44.77
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book7.55

Profitability

EPS (Most Recent Fiscal Year)($1.95)
Net Income$-15,340,000.00
Net Margins-10.87%
Return on Equity-143.33%
Return on Assets-48.40%

Miscellaneous

Employees14
Outstanding Shares8,730,000
Market Cap$34.91

The Truth About Cryptocurrencies

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc (NASDAQ:PLXP) issued its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. The biotechnology company had revenue of $81.46 million for the quarter. PLx Pharma had a negative return on equity of 143.33% and a negative net margin of 10.87%. View PLx Pharma's Earnings History.

What price target have analysts set for PLXP?

3 Wall Street analysts have issued 1-year price objectives for PLx Pharma's shares. Their forecasts range from $12.00 to $14.00. On average, they expect PLx Pharma's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 225.0% from the stock's current price. View Analyst Ratings for PLx Pharma.

What is the consensus analysts' recommendation for PLx Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of PLx Pharma's key competitors?

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the folowing people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 64)
  • Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 77)
  • Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
  • Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50)

When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Has PLx Pharma been receiving favorable news coverage?

Headlines about PLXP stock have been trending positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PLx Pharma earned a media sentiment score of 0.29 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $4.00.

How big of a company is PLx Pharma?

PLx Pharma has a market capitalization of $34.91 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]


MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.